content: <HTML><HEAD>
  <TITLE>Prepared by R.R. Donnelley Financial -- Form 8-K</TITLE>
  </HEAD>
    <BODY BGCOLOR="WHITE">
   <HR SIZE="4" NOSHADE COLOR="#000000" ALIGN="left"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></DIV>
  <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR NOSHADE WIDTH="21%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman"
  SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported): May 7, 2002 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR NOSHADE WIDTH="21%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>CONCEPTUS, INC. </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in charter) </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-27596</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>97-3170244</B></FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="33%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>incorporation or
  organization)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="33%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission file number)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="33%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. employer</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>identification no.)</B></FONT></DIV> </TD> </TR>
  
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1021 Howard Avenue </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman"
  SIZE="2"><B>San Carlos, CA 94070 </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip code) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (650) 802-7240 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="4" NOSHADE COLOR="#000000" ALIGN="left">
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"><B>ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER EVENTS. </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">On May 7, 2002, Conceptus, Inc. issued a press release announcing one-year follow-up data on patients from the Pivotal trial, as presented at the American College of Obstetricians and
  Gynecologists Meeting. Text of the press release follows: </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2"><B>Los Angeles, CA, May 7, 2002</B><B>&#151;</B>Conceptus, Inc.
  (NASDAQ NM: CPTS) today unveiled one year follow-up data on patients from the Pivotal trial of <I>Essure</I></FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><I><SUP>&#153;</SUP></I></FONT><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000"><I><SUP></SUP>, </I>a non-incisional permanent birth control procedure, which found that 92 percent of <I>Essure </I>patients who are employed returned to work in one day or less after the procedure day. These results were presented
  by Professor Rafael Valle, Northwestern University Medical School, at the 50th American College of Obstetricians and Gynecologists Annual Clinical Meeting in Los Angeles, CA. Pivotal trial results also indicated that nearly 60 percent of <I>Essure
  </I>patients were back to their regular physical activities within one day, and within two days 77 percent had resumed regular activities. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT
  FACE="Times New Roman" SIZE="2">An <I>Essure </I>procedure does not require cutting or penetrating the abdomen and can be performed in an average of 13 minutes of hysteroscopic time, and in a less costly procedure setting without general anesthesia.
  In fact, a survey of new <I>Essure </I>investigators found that 80 percent of respondents rated the <I>Essure </I>procedure as &#145;very simple&#146;, &#145;simple&#146; or &#145;moderately simple&#146; when compared to laparoscopic tubal ligation.
  <I>Essure </I>is a permanent procedure that does not involve taking drugs or hormones. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">&#147;For years, the only option
  available for women seeking permanent birth control required an incision, a lengthy recovery period and typically general anesthesia,&#148; said Jay M. Cooper, M.D., founder and medical director of Women&#146;s Health Research Center, Phoenix,
  Arizona, and the principal U.S. investigator of <I>Essure</I>. &#147;The data suggests that the <I>Essure</I> procedure may offer an option that is not as disruptive to their lives, family or work. The positive response from women in this study
  suggests that this may be a preferable option over traditional surgery.&#148; </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">Additional data from the Pivotal trial also
  showed that 96 percent of patients would recommend the procedure to a friend. Furthermore, 99 percent of women who have relied on <I>Essure </I>for birth control rated their long-term comfort as &#145;good&#146; to &#145;excellent&#146;.
  </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">A comparison to laparoscopic tubal ligation was not performed in the pivotal trial; however, published reports show that women
  who undergo surgical tubal ligation&#151;the only permanent birth control option currently available for women in the U.S.&#151;typically return to regular physical activities in four to six days. Furthermore, tubal ligations performed by laparotomy
  have been reported to have an average recovery time of 10 or more days. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">&#147;After having three children, my husband and I
  knew our family was complete and so I was looking for a permanent option. But I really didn&#146;t want to undergo a surgical procedure like tubal ligation,&#148; said Gabriella Avina, a participant in the clinical trial who is also a labor and
  delivery nurse. &#147;After learning of the <I>Essure </I>procedure, I was eager to undergo it. My experience with the procedure itself was simple and took about 20 minutes. I was able to return to my job and my family within a day.&#148;
  </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"><B>Preventing Pregnancy </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT
  FACE="Times New Roman" SIZE="2">To date, in more than 900 woman-years of effectiveness testing, there has not been a reported pregnancy in women relying on <I>Essure </I>for contraception. Like all birth control methods, <I>Essure </I>is not
  expected to be 100 percent effective, and pregnancies are expected. There is a three-month waiting period after the procedure during which women must use an alternative form of birth control. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV>
  <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">Adverse events that ultimately prevented reliance occurred in about 2 percent of women with bilateral placement. Additionally, 3 percent of women experienced minor adverse events on
  the day of the procedure that were resolved prior to discharge with the exception of one woman who was hospitalized overnight due to an adverse reaction to pain medication. Minor side effects such as back/abdominal pain, gas and bloating and
  headache were also infrequently reported. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"><B>Methodology </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT
  FACE="Times New Roman" SIZE="2">Initial enrollment in the <I>Essure</I> pivotal trial was 518 women. Placement of the <I>Essure</I> device was attempted in 507 (98 percent) of these women. Of these 507 women, 92 percent achieved bilateral placement.
  3 percent of the women were found to have pre-existing tubal occlusion, which precluded placement of the device. Of the women with bilateral placement who completed the three-month follow-up visit, 98 percent were ultimately able to rely on the
  device for contraception. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"><B>Permanent Birth Control </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT
  FACE="Times New Roman" SIZE="2">According to the United States Centers for Disease Control and Prevention, surgical tubal ligation continues to be the most prevalent form of birth control in the U.S, with 41 percent of women using contraceptives age
  35-39 and 50 percent of women using contraceptives age 40-44 having had a surgical tubal sterilization. An estimated 700,000 surgical tubal ligations are performed each year in the United States, despite the fact that it is invasive and costly.
  About 93 percent of the laparoscopic procedures in the U.S. are performed in a hospital or surgi-center under general anesthesia, requiring between four and five hours of hospital recovery time and four to six days before returning to regular
  activities. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">Development of a non-incisional method of tubal ligation has been an elusive goal for researchers since the
  1970&#146;s. <I>Essure</I> is currently an investigational device for non-incisional permanent birth control. On April 19, 2002, Conceptus submitting its PMA to the FDA, and is seeking approval to market <I>Essure </I>in the United States. <B></B>
  </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"><B>About Conceptus </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman"
  SIZE="2">Conceptus, Inc. is developing <I>Essure</I>, an innovative medical procedure, designed to provide a non-incisional alternative to tubal ligation, the leading form of birth control worldwide. The availability of <I>Essure </I>in the U.S. is
  projected for 2003 and is expected to open up a market currently occupied by surgical tubal ligation and vasectomy, which combined account for over 1 million procedures in the United States. </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">The <I>Essure </I>procedure is based on a unique and proprietary implant and catheter delivery
  system for minimally invasive transcervical tubal access. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2"><I>Except for the historical information contained herein, the
  matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of
  and market demand for our product, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company&#146;s
  control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company&#146;s control, such as delays by regulatory authorities, scientific advances by third parties and introduction
  of competitive products, as well as those factors set forth in the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and Exchange Commission. </I></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="right">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" COLSPAN="3" WIDTH="43%"> <DIV><FONT FACE="Times New Roman" SIZE="2">C<SMALL>ONCEPTUS</SMALL>, I<SMALL>NC</SMALL>.</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">(Registrant)</FONT></DIV> </TD> </TR>
  <TR>
  <TD HEIGHT="32"> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="3%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="43%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;G<SMALL>LEN</SMALL> K. F<SMALL>URUTA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></DIV> <HR NOSHADE
  COLOR="#000000" ALIGN="left"></TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="43%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Glen K. Furuta</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Vice President, Finance &amp;
  Administration</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>and Chief Financial Officer</B></FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Dated:&nbsp;&nbsp;May 16, 2002 </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></DIV>
  
   </BODY></HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 16778}]
metadata_filer: {"company-data": {"conformed-name": "CONCEPTUS INC", "cik": "0000896778", "assigned-sic": "3841", "irs-number": "973170244", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27596", "film-number": "02654780"}, "business-address": {"street1": "1021 HOWARD AVE", "city": "SAN CARLOS", "state": "CA", "zip": "94070", "phone": "4158027240"}, "mail-address": {"street1": "1021 HOWARD AVENUE", "city": "SAN CARLOS", "state": "CA", "zip": "94070"}}
text: Prepared by R.R. Donnelley Financial -- Form 8-K
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  PURSUANT TO SECTION 13 OR 15(D) OF THE
  SECURITIES EXCHANGE ACT OF 1934
  Date of Report (Date of earliest event reported): May 7, 2002
  CONCEPTUS, INC.
  (Exact name of registrant as specified in charter)
  Delaware
  000-27596
  97-3170244
  (State or other jurisdiction of
  incorporation or
  organization)
  (Commission file number)
  (I.R.S. employer
  identification no.)
  1021 Howard Avenue
  San Carlos, CA 94070
  (Address of principal executive offices) (Zip code)
  Registrant's telephone number, including area code: (650) 802-7240
  ITEM 5.    OTHER EVENTS.
  On May 7, 2002, Conceptus, Inc. issued a press release announcing one-year follow-up data on patients from the Pivotal trial, as presented at the American College of Obstetricians and
  Gynecologists Meeting. Text of the press release follows:
  Los Angeles, CA, May 7, 2002
  —
  Conceptus, Inc.
  (NASDAQ NM: CPTS) today unveiled one year follow-up data on patients from the Pivotal trial of
  Essure
  ™
  ,
  a non-incisional permanent birth control procedure, which found that 92 percent of
  Essure
  patients who are employed returned to work in one day or less after the procedure day. These results were presented
  by Professor Rafael Valle, Northwestern University Medical School, at the 50th American College of Obstetricians and Gynecologists Annual Clinical Meeting in Los Angeles, CA. Pivotal trial results also indicated that nearly 60 percent of
  Essure
  patients were back to their regular physical activities within one day, and within two days 77 percent had resumed regular activities.
  An
  Essure
  procedure does not require cutting or penetrating the abdomen and can be performed in an average of 13 minutes of hysteroscopic time, and in a less costly procedure setting without general anesthesia.
  In fact, a survey of new
  Essure
  investigators found that 80 percent of respondents rated the
  Essure
  procedure as 'very simple', 'simple' or 'moderately simple' when compared to laparoscopic tubal ligation.
  Essure
  is a permanent procedure that does not involve taking drugs or hormones.
  "For years, the only option
  available for women seeking permanent birth control required an incision, a lengthy recovery period and typically general anesthesia," said Jay M. Cooper, M.D., founder and medical director of Women's Health Research Center, Phoenix,
  Arizona, and the principal U.S. investigator of
  Essure
  . "The data suggests that the
  Essure
  procedure may offer an option that is not as disruptive to their lives, family or work. The positive response from women in this study
  suggests that this may be a preferable option over traditional surgery."
  Additional data from the Pivotal trial also
  showed that 96 percent of patients would recommend the procedure to a friend. Furthermore, 99 percent of women who have relied on
  Essure
  for birth control rated their long-term comfort as 'good' to 'excellent'.
  A comparison to laparoscopic tubal ligation was not performed in the pivotal trial; however, published reports show that women
  who undergo surgical tubal ligation—the only permanent birth control option currently available for women in the U.S.—typically return to regular physical activities in four to six days. Furthermore, tubal ligations performed by laparotomy
  have been reported to have an average recovery time of 10 or more days.
  "After having three children, my husband and I
  knew our family was complete and so I was looking for a permanent option. But I really didn't want to undergo a surgical procedure like tubal ligation," said Gabriella Avina, a participant in the clinical trial who is also a labor and
  delivery nurse. "After learning of the
  Essure
  procedure, I was eager to undergo it. My experience with the procedure itself was simple and took about 20 minutes. I was able to return to my job and my family within a day."
  2
  Preventing Pregnancy
  To date, in more than 900 woman-years of effectiveness testing, there has not been a reported pregnancy in women relying on
  Essure
  for contraception. Like all birth control methods,
  Essure
  is not
  expected to be 100 percent effective, and pregnancies are expected. There is a three-month waiting period after the procedure during which women must use an alternative form of birth control.
  Adverse events that ultimately prevented reliance occurred in about 2 percent of women with bilateral placement. Additionally, 3 percent of women experienced minor adverse events on
  the day of the procedure that were resolved prior to discharge with the exception of one woman who was hospitalized overnight due to an adverse reaction to pain medication. Minor side effects such as back/abdominal pain, gas and bloating and
  headache were also infrequently reported.
  Methodology
  Initial enrollment in the
  Essure
  pivotal trial was 518 women. Placement of the
  Essure
  device was attempted in 507 (98 percent) of these women. Of these 507 women, 92 percent achieved bilateral placement.
  3 percent of the women were found to have pre-existing tubal occlusion, which precluded placement of the device. Of the women with bilateral placement who completed the three-month follow-up visit, 98 percent were ultimately able to rely on the
  device for contraception.
  Permanent Birth Control
  According to the United States Centers for Disease Control and Prevention, surgical tubal ligation continues to be the most prevalent form of birth control in the U.S, with 41 percent of women using contraceptives age
  35-39 and 50 percent of women using contraceptives age 40-44 having had a surgical tubal sterilization. An estimated 700,000 surgical tubal ligations are performed each year in the United States, despite the fact that it is invasive and costly.
  About 93 percent of the laparoscopic procedures in the U.S. are performed in a hospital or surgi-center under general anesthesia, requiring between four and five hours of hospital recovery time and four to six days before returning to regular
  activities.
  Development of a non-incisional method of tubal ligation has been an elusive goal for researchers since the
  1970's.
  Essure
  is currently an investigational device for non-incisional permanent birth control. On April 19, 2002, Conceptus submitting its PMA to the FDA, and is seeking approval to market
  Essure
  in the United States.
  About Conceptus
  Conceptus, Inc. is developing
  Essure
  , an innovative medical procedure, designed to provide a non-incisional alternative to tubal ligation, the leading form of birth control worldwide. The availability of
  Essure
  in the U.S. is
  projected for 2003 and is expected to open up a market currently occupied by surgical tubal ligation and vasectomy, which combined account for over 1 million procedures in the United States.
  3
  The
  Essure
  procedure is based on a unique and proprietary implant and catheter delivery
  system for minimally invasive transcervical tubal access.
  Except for the historical information contained herein, the
  matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of
  and market demand for our product, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company's
  control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as delays by regulatory authorities, scientific advances by third parties and introduction
  of competitive products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and Exchange Commission.
  ###
  4
  SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  C
  ONCEPTUS
  , I
  NC
  .
  (Registrant)
  By:
  /s/    G
  LEN
  K. F
  URUTA
  Glen K. Furuta
  Vice President, Finance &
  Administration
  and Chief Financial Officer
  Dated:  May 16, 2002
  5